The Group's principal activities are to develop, produce, market and sell innovative, over-the-counter (OTC) healthcare products. The Group through its subsidiaries markets and sells products under the Zicam brand. Its current Zicam products are marketed in the cough and cold market category. The market in retail sales includes a wide variety of tablets, liquids, gels, sprays, and syrups that remedy and/or provide relief to cold, allergy and sinus congestion sufferers. The largest sub-segment of the cough and cold category includes products formulated to relieve symptoms associated with the common cold or allergies. The Group sells its products directly to major food, drug, mass market and wholesale warehouse retailers throughout the United States and to distributors that sell to smaller retail establishments.
Alacra Alerts:
Receive alerts on the latest reports on Matrixx Initiatives, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
